文献速递头颈部肿瘤放疗中枢神经肿瘤放疗

诱导化疗联合生物放疗治疗局部晚期复发鼻咽癌的前瞻性多中心二期试验

Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-12-01

该二期研究纳入33例局部晚期复发鼻咽癌(rNPC)患者,评估诱导多西他赛+顺铂+氟尿嘧啶(TPF)后每周多西他赛+西妥昔单抗同步调强放疗的疗效与安全性。全组3年无进展生存率35.7%、总生存率63.8%;可评估26例中完全缓解率30.8%,3年局部区域控制率49.2%。但诱导TPF耐受性差且颞叶坏死发生率高,限制其临床试验外应用。

要点

  • 全组3年PFS 35.7%、OS 63.8%,可评估者完全缓解率30.8%。
  • 3年局部区域控制率49.2%,8例发生颞叶坏死。
  • 5例死于治疗相关并发症,诱导TPF耐受性差限制应用。

核心结论

  • 该挽救治疗方案对晚期局部复发鼻咽癌可取得优于既往研究的结果,但诱导TPF耐受性差及颞叶坏死率高限制其临床试验外应用。

研究设计与样本

  • 前瞻性多中心二期试验纳入33例rNPC(T3-T4、N0-N1、M0)患者,其中19例(57.6%)为rT3、其余为rT4,8例复发时伴rN1。
  • 治疗方案为诱导TPF后每周多西他赛+西妥昔单抗同步调强放疗,评估治疗结局与安全性。

主要发现

  • 中位随访28.5个月,全组3年无进展生存率35.7%、总生存率63.8%。
  • 可评估的26例中完全缓解率30.8%,3年局部区域控制率49.2%。
  • 8例发生颞叶坏死;≥3级听力丧失、软组织坏死、吞咽困难、牙关紧闭发生率分别为30.8%、15.4%、11.5%、19.2%。
  • 1例在TPF1周期后死亡,5例因≥3级毒性在诱导期退出,27例完成全疗程但1例评估前死亡;共5例死于急性或晚期治疗相关并发症(2例鼻出血、1例颞叶坏死等)。

临床怎么用

  • 该方案可用于局部晚期rNPC的挽救治疗探索,但需密切监测诱导TPF毒性及颞叶坏死等晚期并发症。

局限性

  • 诱导TPF耐受性差及颞叶坏死发生率高,限制该方案在临床试验外的适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate, in a phase 2 study, whether induction docetaxel, cisplatin, and fluorouracil (TPF) followed by weekly docetaxel and cetuximab in concurrence with intensity modulated radiation therapy can improve the treatment outcome for patients with advanced locally recurrent nasopharyngeal carcinoma (rNPC). METHODS AND MATERIALS: Thirty-three patients with rNPC (T3-T4, N0-N1, M0) were recruited. Of these, 19 patients (57.6%) had stage rT3 recurrence, and the rest had stage rT4. Eight patients also had rN1 at the time of relapse. Treatment outcomes and safety were evaluated. RESULTS: Among these 33 patients, 1 died after 1 cycle of TPF, 5 patients withdrew from the study during the induction period because of grade ≥3 toxicities; 27 patients completed the whole course of treatment, but 1 died before any assessment could be made. The median follow-up period was 28.5 months. The progression-free survival and overall survival at 3 years for the whole group were 35.7% and 63.8%, respectively. Among the 26 patients who could be assessed after treatment, the complete response rate was 30.8%, and the locoregional control rate at 3 years was 49.2%. Temporal lobe necrosis (TLN) developed in 8 cases. The rates of grade ≥3 hearing loss, soft tissue necrosis, dysphagia, and trismus were 30.8%, 15.4%, 11.5%, and 19.2%, respectively. Overall, 5 patients died owing to acute (1 after cycle 1 TPF and 1 after completion of bio-chemoradiotherapy) or late (2 epistaxis and 1 TLN) treatment-related complications. CONCLUSIONS: The proposed salvage treatment regimen for advanced locally recurrent NPC could achieve a better treatment outcome than seen in previous studies. However, poor tolerability of induction TPF and the high rate of TLN limit its applicability outside clinical trials.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ng WT, Ngan RKC, Kwong DLW, et al. Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2017. PMID: 29413277. doi:10.1016/j.ijrobp.2017.11.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。